Nugen's EziAutoJector receives NHS drug tariff approval

Mr. Liang Lin reports NUGEN MEDICAL DEVICES ANNOUNCES NHS DRUG TARIFF APPROVAL FOR EZIAUTOJECTOR(R) PRODUCT LINE IN THE UK Nugen Medical Devices Inc.'s exclusive U.K. distribution partner, EziAutoJector Ltd., has received confirmation from the NHS Business Services Authority, on behalf of the Department of Health, that EziAutoJector products have been approved for inclusion in the NHS drug tariff. This milestone provides for individuals with diabetes who are prescribed EziAutoJector by their health care provider to receive the EziAutoJector needle-free insulin delivery device and its accessories at no cost, as part of their NHS-funded diabetes care. Aligning with the National Institute for Health and Care Excellence (NICE) guidelines, which advocate for personalized patient choice in insulin delivery methods, this should then ensure pharmacists are reimbursed for dispensing the product. EziAutoJector has established supply channels through a major pharmaceutical wholesaler, enabling distribution to both high-street pharmacies and direct-to-patient via on-line pharmacy services. EziAutoJector's U.K. market strategy includes targeted educational initiatives designed to engage diabetes health care professionals, pharmacists, patients and caregivers -- aimed at increasing awareness, understanding and advocacy for the EziAutoJector product range. Additionally, a direct-to-consumer (D2C) e-commerce channel will support patients in regions where prescribing restrictions currently limit access, ensuring broader availability of the technology. By transitioning to EziAutoJector, each patient eliminates the use of over 1,000 single-use insulin needles annually -- significantly reducing biohazardous waste and the environmental footprint associated with its collection and disposal. This contributes to a more sustainable approach to diabetes management and supports the NHS in achieving its environmental and cost-efficiency goals. "NHS reimbursement approval marks a significant step forward for EziAutoJector Ltd. and for Nugen Medical Devices," said Liang Lin, chief executive officer of Nugen Medical Devices. "It enables people living with diabetes to benefit from needle-free insulin delivery and supports clinicians in delivering truly individualized care with reimbursement making easy patient access." About Nugen Medical Devices Inc. Nugen develops next-generation needle-free devices for subcutaneous drug delivery. Its flagship InsuJet system is approved in 42 countries and is designed to improve the lives of millions of people with diabetes worldwide. We seek Safe Harbor.